nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP2E1—Ritonavir—acquired immunodeficiency syndrome	0.0639	0.0911	CbGbCtD
Dexmedetomidine—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0573	0.0818	CbGbCtD
Dexmedetomidine—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0539	0.0769	CbGbCtD
Dexmedetomidine—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0539	0.0769	CbGbCtD
Dexmedetomidine—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0487	0.0696	CbGbCtD
Dexmedetomidine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0472	0.0674	CbGbCtD
Dexmedetomidine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0444	0.0634	CbGbCtD
Dexmedetomidine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0444	0.0634	CbGbCtD
Dexmedetomidine—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0408	0.0583	CbGbCtD
Dexmedetomidine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0402	0.0573	CbGbCtD
Dexmedetomidine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0402	0.0573	CbGbCtD
Dexmedetomidine—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0369	0.0527	CbGbCtD
Dexmedetomidine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0347	0.0495	CbGbCtD
Dexmedetomidine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0337	0.048	CbGbCtD
Dexmedetomidine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0304	0.0434	CbGbCtD
Dexmedetomidine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0304	0.0434	CbGbCtD
Dexmedetomidine—SLC6A2—nerve—acquired immunodeficiency syndrome	0.00249	0.0752	CbGeAlD
Dexmedetomidine—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.00145	0.0437	CbGeAlD
Dexmedetomidine—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.00133	0.0402	CbGeAlD
Dexmedetomidine—CYP2E1—blood plasma—acquired immunodeficiency syndrome	0.0013	0.0393	CbGeAlD
Dexmedetomidine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.00103	0.0311	CbGeAlD
Dexmedetomidine—ADRA1B—nervous system—acquired immunodeficiency syndrome	0.000926	0.028	CbGeAlD
Dexmedetomidine—ADRA1D—nervous system—acquired immunodeficiency syndrome	0.000906	0.0274	CbGeAlD
Dexmedetomidine—ADRA1B—central nervous system—acquired immunodeficiency syndrome	0.000891	0.0269	CbGeAlD
Dexmedetomidine—ADRA1D—central nervous system—acquired immunodeficiency syndrome	0.000872	0.0263	CbGeAlD
Dexmedetomidine—ADRA1B—brain—acquired immunodeficiency syndrome	0.000708	0.0214	CbGeAlD
Dexmedetomidine—ADRA1D—brain—acquired immunodeficiency syndrome	0.000692	0.0209	CbGeAlD
Dexmedetomidine—CYP1A1—skin of body—acquired immunodeficiency syndrome	0.000686	0.0207	CbGeAlD
Dexmedetomidine—ADRA2C—blood—acquired immunodeficiency syndrome	0.00061	0.0184	CbGeAlD
Dexmedetomidine—SLC6A2—lung—acquired immunodeficiency syndrome	0.000604	0.0183	CbGeAlD
Dexmedetomidine—ADRA2C—spinal cord—acquired immunodeficiency syndrome	0.000588	0.0178	CbGeAlD
Dexmedetomidine—ADRA2C—vagina—acquired immunodeficiency syndrome	0.000566	0.0171	CbGeAlD
Dexmedetomidine—SLC6A2—nervous system—acquired immunodeficiency syndrome	0.000559	0.0169	CbGeAlD
Dexmedetomidine—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000556	0.0168	CbGeAlD
Dexmedetomidine—CYP1A1—digestive system—acquired immunodeficiency syndrome	0.000549	0.0166	CbGeAlD
Dexmedetomidine—SLC6A2—central nervous system—acquired immunodeficiency syndrome	0.000539	0.0163	CbGeAlD
Dexmedetomidine—ADRA2C—lung—acquired immunodeficiency syndrome	0.000535	0.0162	CbGeAlD
Dexmedetomidine—CYP1A2—blood—acquired immunodeficiency syndrome	0.00053	0.016	CbGeAlD
Dexmedetomidine—CYP1A1—blood—acquired immunodeficiency syndrome	0.000523	0.0158	CbGeAlD
Dexmedetomidine—CYP2E1—lymphoid tissue—acquired immunodeficiency syndrome	0.000506	0.0153	CbGeAlD
Dexmedetomidine—CYP2E1—digestive system—acquired immunodeficiency syndrome	0.0005	0.0151	CbGeAlD
Dexmedetomidine—ADRA2C—nervous system—acquired immunodeficiency syndrome	0.000496	0.015	CbGeAlD
Dexmedetomidine—ADRA2A—blood—acquired immunodeficiency syndrome	0.000487	0.0147	CbGeAlD
Dexmedetomidine—CYP1A1—vagina—acquired immunodeficiency syndrome	0.000484	0.0146	CbGeAlD
Dexmedetomidine—ADRA2C—central nervous system—acquired immunodeficiency syndrome	0.000477	0.0144	CbGeAlD
Dexmedetomidine—CYP2E1—blood—acquired immunodeficiency syndrome	0.000477	0.0144	CbGeAlD
Dexmedetomidine—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.000469	0.0142	CbGeAlD
Dexmedetomidine—CYP1A2—lung—acquired immunodeficiency syndrome	0.000464	0.014	CbGeAlD
Dexmedetomidine—CYP2E1—spinal cord—acquired immunodeficiency syndrome	0.000459	0.0139	CbGeAlD
Dexmedetomidine—CYP1A1—lung—acquired immunodeficiency syndrome	0.000458	0.0138	CbGeAlD
Dexmedetomidine—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000452	0.0136	CbGeAlD
Dexmedetomidine—SLC6A2—brain—acquired immunodeficiency syndrome	0.000428	0.0129	CbGeAlD
Dexmedetomidine—ADRA2A—lung—acquired immunodeficiency syndrome	0.000427	0.0129	CbGeAlD
Dexmedetomidine—CYP1A1—nervous system—acquired immunodeficiency syndrome	0.000424	0.0128	CbGeAlD
Dexmedetomidine—CYP2E1—lung—acquired immunodeficiency syndrome	0.000418	0.0126	CbGeAlD
Dexmedetomidine—SLC6A2—lymph node—acquired immunodeficiency syndrome	0.000413	0.0125	CbGeAlD
Dexmedetomidine—CYP1A1—central nervous system—acquired immunodeficiency syndrome	0.000408	0.0123	CbGeAlD
Dexmedetomidine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000396	0.012	CbGeAlD
Dexmedetomidine—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000395	0.0119	CbGeAlD
Dexmedetomidine—CYP2E1—nervous system—acquired immunodeficiency syndrome	0.000387	0.0117	CbGeAlD
Dexmedetomidine—Pain—Nevirapine—acquired immunodeficiency syndrome	0.000382	0.00144	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Ritonavir—acquired immunodeficiency syndrome	0.000381	0.00144	CcSEcCtD
Dexmedetomidine—Visual impairment—Saquinavir—acquired immunodeficiency syndrome	0.000381	0.00144	CcSEcCtD
Dexmedetomidine—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.000381	0.0115	CbGeAlD
Dexmedetomidine—Dyspnoea—Abacavir—acquired immunodeficiency syndrome	0.000379	0.00143	CcSEcCtD
Dexmedetomidine—ADRA2C—brain—acquired immunodeficiency syndrome	0.000379	0.0114	CbGeAlD
Dexmedetomidine—Confusional state—Zidovudine—acquired immunodeficiency syndrome	0.000378	0.00143	CcSEcCtD
Dexmedetomidine—CYP2D6—blood—acquired immunodeficiency syndrome	0.000377	0.0114	CbGeAlD
Dexmedetomidine—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000374	0.00141	CcSEcCtD
Dexmedetomidine—Anaemia—Efavirenz—acquired immunodeficiency syndrome	0.000373	0.00141	CcSEcCtD
Dexmedetomidine—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000373	0.00141	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.000373	0.00141	CcSEcCtD
Dexmedetomidine—Angiopathy—Ritonavir—acquired immunodeficiency syndrome	0.000372	0.0014	CcSEcCtD
Dexmedetomidine—CYP2E1—central nervous system—acquired immunodeficiency syndrome	0.000372	0.0113	CbGeAlD
Dexmedetomidine—Agitation—Efavirenz—acquired immunodeficiency syndrome	0.000371	0.0014	CcSEcCtD
Dexmedetomidine—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.00037	0.0014	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.00037	0.0014	CcSEcCtD
Dexmedetomidine—Pain—Stavudine—acquired immunodeficiency syndrome	0.000369	0.00139	CcSEcCtD
Dexmedetomidine—Constipation—Stavudine—acquired immunodeficiency syndrome	0.000369	0.00139	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Nevirapine—acquired immunodeficiency syndrome	0.000368	0.00139	CcSEcCtD
Dexmedetomidine—Chills—Ritonavir—acquired immunodeficiency syndrome	0.000368	0.00139	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Zidovudine—acquired immunodeficiency syndrome	0.000367	0.00139	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.000367	0.00138	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Saquinavir—acquired immunodeficiency syndrome	0.000367	0.00138	CcSEcCtD
Dexmedetomidine—ADRA2C—lymph node—acquired immunodeficiency syndrome	0.000366	0.0111	CbGeAlD
Dexmedetomidine—Gastrointestinal pain—Nevirapine—acquired immunodeficiency syndrome	0.000366	0.00138	CcSEcCtD
Dexmedetomidine—Pain—Abacavir—acquired immunodeficiency syndrome	0.000364	0.00137	CcSEcCtD
Dexmedetomidine—Anxiety—Indinavir—acquired immunodeficiency syndrome	0.000363	0.00137	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Zidovudine—acquired immunodeficiency syndrome	0.000363	0.00137	CcSEcCtD
Dexmedetomidine—Mental disorder—Ritonavir—acquired immunodeficiency syndrome	0.00036	0.00136	CcSEcCtD
Dexmedetomidine—Angiopathy—Saquinavir—acquired immunodeficiency syndrome	0.000359	0.00135	CcSEcCtD
Dexmedetomidine—Malnutrition—Ritonavir—acquired immunodeficiency syndrome	0.000357	0.00135	CcSEcCtD
Dexmedetomidine—Anaemia—Delavirdine—acquired immunodeficiency syndrome	0.000357	0.00135	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Nelfinavir—acquired immunodeficiency syndrome	0.000357	0.00135	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000356	0.00134	CcSEcCtD
Dexmedetomidine—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.000356	0.00134	CcSEcCtD
Dexmedetomidine—Agitation—Delavirdine—acquired immunodeficiency syndrome	0.000355	0.00134	CcSEcCtD
Dexmedetomidine—Chills—Saquinavir—acquired immunodeficiency syndrome	0.000355	0.00134	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000354	0.00134	CcSEcCtD
Dexmedetomidine—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.000353	0.00133	CcSEcCtD
Dexmedetomidine—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000353	0.00133	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.000353	0.00133	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.00035	0.00132	CcSEcCtD
Dexmedetomidine—Convulsion—Efavirenz—acquired immunodeficiency syndrome	0.00035	0.00132	CcSEcCtD
Dexmedetomidine—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.000349	0.00132	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.000348	0.00131	CcSEcCtD
Dexmedetomidine—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000347	0.00131	CcSEcCtD
Dexmedetomidine—Mental disorder—Saquinavir—acquired immunodeficiency syndrome	0.000346	0.00131	CcSEcCtD
Dexmedetomidine—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	0.000344	0.0013	CcSEcCtD
Dexmedetomidine—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000344	0.0013	CcSEcCtD
Dexmedetomidine—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000344	0.0013	CcSEcCtD
Dexmedetomidine—Anxiety—Efavirenz—acquired immunodeficiency syndrome	0.000343	0.00129	CcSEcCtD
Dexmedetomidine—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000342	0.00129	CcSEcCtD
Dexmedetomidine—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000342	0.00129	CcSEcCtD
Dexmedetomidine—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000342	0.00129	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Indinavir—acquired immunodeficiency syndrome	0.000342	0.00129	CcSEcCtD
Dexmedetomidine—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000341	0.00129	CcSEcCtD
Dexmedetomidine—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000341	0.00129	CcSEcCtD
Dexmedetomidine—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.00034	0.00128	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.00034	0.00128	CcSEcCtD
Dexmedetomidine—Chills—Lamivudine—acquired immunodeficiency syndrome	0.000338	0.00128	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.000337	0.00127	CcSEcCtD
Dexmedetomidine—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000336	0.00127	CcSEcCtD
Dexmedetomidine—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000336	0.00127	CcSEcCtD
Dexmedetomidine—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000336	0.00127	CcSEcCtD
Dexmedetomidine—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000334	0.00126	CcSEcCtD
Dexmedetomidine—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000334	0.00126	CcSEcCtD
Dexmedetomidine—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000334	0.00126	CcSEcCtD
Dexmedetomidine—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.000332	0.00125	CcSEcCtD
Dexmedetomidine—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.00033	0.00125	CcSEcCtD
Dexmedetomidine—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.000328	0.00124	CcSEcCtD
Dexmedetomidine—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000328	0.00124	CcSEcCtD
Dexmedetomidine—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.000328	0.00124	CcSEcCtD
Dexmedetomidine—CYP1A1—brain—acquired immunodeficiency syndrome	0.000324	0.0098	CbGeAlD
Dexmedetomidine—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000324	0.00122	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000324	0.00122	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000323	0.00122	CcSEcCtD
Dexmedetomidine—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000322	0.00121	CcSEcCtD
Dexmedetomidine—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000322	0.00121	CcSEcCtD
Dexmedetomidine—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000321	0.00121	CcSEcCtD
Dexmedetomidine—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000321	0.00121	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000319	0.0012	CcSEcCtD
Dexmedetomidine—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000318	0.0012	CcSEcCtD
Dexmedetomidine—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.000318	0.0012	CcSEcCtD
Dexmedetomidine—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000316	0.00119	CcSEcCtD
Dexmedetomidine—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000316	0.00119	CcSEcCtD
Dexmedetomidine—Rash—Didanosine—acquired immunodeficiency syndrome	0.000313	0.00118	CcSEcCtD
Dexmedetomidine—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000313	0.00118	CcSEcCtD
Dexmedetomidine—CYP1A1—lymph node—acquired immunodeficiency syndrome	0.000313	0.00947	CbGeAlD
Dexmedetomidine—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000313	0.00118	CcSEcCtD
Dexmedetomidine—Headache—Didanosine—acquired immunodeficiency syndrome	0.000311	0.00117	CcSEcCtD
Dexmedetomidine—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000311	0.00117	CcSEcCtD
Dexmedetomidine—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.00031	0.00117	CcSEcCtD
Dexmedetomidine—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.00031	0.00117	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000309	0.00117	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000309	0.00116	CcSEcCtD
Dexmedetomidine—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000309	0.00116	CcSEcCtD
Dexmedetomidine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000308	0.00116	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000307	0.00116	CcSEcCtD
Dexmedetomidine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000306	0.00925	CbGeAlD
Dexmedetomidine—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000306	0.00115	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000305	0.00115	CcSEcCtD
Dexmedetomidine—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000303	0.00114	CcSEcCtD
Dexmedetomidine—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000303	0.00114	CcSEcCtD
Dexmedetomidine—ADRA2A—brain—acquired immunodeficiency syndrome	0.000302	0.00913	CbGeAlD
Dexmedetomidine—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000301	0.00114	CcSEcCtD
Dexmedetomidine—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000298	0.00113	CcSEcCtD
Dexmedetomidine—Pain—Indinavir—acquired immunodeficiency syndrome	0.000298	0.00113	CcSEcCtD
Dexmedetomidine—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000298	0.00112	CcSEcCtD
Dexmedetomidine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000298	0.00112	CcSEcCtD
Dexmedetomidine—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000297	0.00112	CcSEcCtD
Dexmedetomidine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000297	0.00112	CcSEcCtD
Dexmedetomidine—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000297	0.00112	CcSEcCtD
Dexmedetomidine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000296	0.00112	CcSEcCtD
Dexmedetomidine—CYP2E1—brain—acquired immunodeficiency syndrome	0.000296	0.00893	CbGeAlD
Dexmedetomidine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000295	0.00111	CcSEcCtD
Dexmedetomidine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000295	0.00111	CcSEcCtD
Dexmedetomidine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000295	0.00891	CbGeAlD
Dexmedetomidine—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000295	0.00111	CcSEcCtD
Dexmedetomidine—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000294	0.00111	CcSEcCtD
Dexmedetomidine—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000294	0.00111	CcSEcCtD
Dexmedetomidine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000293	0.00111	CcSEcCtD
Dexmedetomidine—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.000292	0.00882	CbGeAlD
Dexmedetomidine—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000292	0.0011	CcSEcCtD
Dexmedetomidine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000291	0.0011	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000288	0.00108	CcSEcCtD
Dexmedetomidine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000286	0.00108	CcSEcCtD
Dexmedetomidine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000286	0.00108	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000286	0.00108	CcSEcCtD
Dexmedetomidine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000285	0.00108	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000285	0.00108	CcSEcCtD
Dexmedetomidine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000285	0.00107	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000285	0.00107	CcSEcCtD
Dexmedetomidine—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000284	0.00107	CcSEcCtD
Dexmedetomidine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000284	0.00107	CcSEcCtD
Dexmedetomidine—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000283	0.00107	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000282	0.00106	CcSEcCtD
Dexmedetomidine—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000282	0.00106	CcSEcCtD
Dexmedetomidine—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000282	0.00106	CcSEcCtD
Dexmedetomidine—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000282	0.00106	CcSEcCtD
Dexmedetomidine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000282	0.00106	CcSEcCtD
Dexmedetomidine—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000281	0.00106	CcSEcCtD
Dexmedetomidine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000281	0.00106	CcSEcCtD
Dexmedetomidine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.00028	0.00106	CcSEcCtD
Dexmedetomidine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00028	0.00106	CcSEcCtD
Dexmedetomidine—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000279	0.00105	CcSEcCtD
Dexmedetomidine—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000278	0.00105	CcSEcCtD
Dexmedetomidine—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000276	0.00104	CcSEcCtD
Dexmedetomidine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000276	0.00104	CcSEcCtD
Dexmedetomidine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000275	0.00104	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000275	0.00104	CcSEcCtD
Dexmedetomidine—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000274	0.00104	CcSEcCtD
Dexmedetomidine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000273	0.00103	CcSEcCtD
Dexmedetomidine—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000273	0.00103	CcSEcCtD
Dexmedetomidine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000273	0.00103	CcSEcCtD
Dexmedetomidine—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000273	0.00103	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000272	0.00103	CcSEcCtD
Dexmedetomidine—Rash—Stavudine—acquired immunodeficiency syndrome	0.000272	0.00103	CcSEcCtD
Dexmedetomidine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000272	0.00103	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000272	0.00102	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000271	0.00102	CcSEcCtD
Dexmedetomidine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000271	0.00102	CcSEcCtD
Dexmedetomidine—Headache—Stavudine—acquired immunodeficiency syndrome	0.00027	0.00102	CcSEcCtD
Dexmedetomidine—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.00027	0.00102	CcSEcCtD
Dexmedetomidine—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.00027	0.00102	CcSEcCtD
Dexmedetomidine—Pain—Delavirdine—acquired immunodeficiency syndrome	0.00027	0.00102	CcSEcCtD
Dexmedetomidine—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.00027	0.00102	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.00027	0.00102	CcSEcCtD
Dexmedetomidine—Rash—Abacavir—acquired immunodeficiency syndrome	0.000268	0.00101	CcSEcCtD
Dexmedetomidine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000268	0.00101	CcSEcCtD
Dexmedetomidine—Headache—Abacavir—acquired immunodeficiency syndrome	0.000266	0.001	CcSEcCtD
Dexmedetomidine—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000266	0.001	CcSEcCtD
Dexmedetomidine—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000266	0.001	CcSEcCtD
Dexmedetomidine—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000262	0.000989	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000262	0.000989	CcSEcCtD
Dexmedetomidine—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000261	0.000983	CcSEcCtD
Dexmedetomidine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000261	0.000983	CcSEcCtD
Dexmedetomidine—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.00026	0.000981	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.00026	0.00098	CcSEcCtD
Dexmedetomidine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000259	0.000978	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000259	0.000976	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000258	0.000973	CcSEcCtD
Dexmedetomidine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000257	0.00097	CcSEcCtD
Dexmedetomidine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000257	0.000968	CcSEcCtD
Dexmedetomidine—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000256	0.000967	CcSEcCtD
Dexmedetomidine—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000253	0.000953	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000252	0.00095	CcSEcCtD
Dexmedetomidine—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.00025	0.000944	CcSEcCtD
Dexmedetomidine—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.00025	0.000944	CcSEcCtD
Dexmedetomidine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.00025	0.000941	CcSEcCtD
Dexmedetomidine—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000249	0.000941	CcSEcCtD
Dexmedetomidine—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000249	0.000941	CcSEcCtD
Dexmedetomidine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000249	0.00094	CcSEcCtD
Dexmedetomidine—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000249	0.00094	CcSEcCtD
Dexmedetomidine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000248	0.000936	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000242	0.000914	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.00024	0.000907	CcSEcCtD
Dexmedetomidine—Pain—Saquinavir—acquired immunodeficiency syndrome	0.00024	0.000905	CcSEcCtD
Dexmedetomidine—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.00024	0.000905	CcSEcCtD
Dexmedetomidine—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000239	0.000901	CcSEcCtD
Dexmedetomidine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000239	0.0009	CcSEcCtD
Dexmedetomidine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000239	0.0009	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000239	0.0009	CcSEcCtD
Dexmedetomidine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000238	0.000898	CcSEcCtD
Dexmedetomidine—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000237	0.000892	CcSEcCtD
Dexmedetomidine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000236	0.000891	CcSEcCtD
Dexmedetomidine—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000235	0.000886	CcSEcCtD
Dexmedetomidine—CYP2D6—brain—acquired immunodeficiency syndrome	0.000234	0.00707	CbGeAlD
Dexmedetomidine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000231	0.000873	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000231	0.000872	CcSEcCtD
Dexmedetomidine—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000231	0.00087	CcSEcCtD
Dexmedetomidine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000231	0.00087	CcSEcCtD
Dexmedetomidine—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000231	0.00087	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.00023	0.000866	CcSEcCtD
Dexmedetomidine—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000229	0.000864	CcSEcCtD
Dexmedetomidine—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000229	0.000864	CcSEcCtD
Dexmedetomidine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000226	0.000851	CcSEcCtD
Dexmedetomidine—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000223	0.00084	CcSEcCtD
Dexmedetomidine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000222	0.000837	CcSEcCtD
Dexmedetomidine—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000222	0.000837	CcSEcCtD
Dexmedetomidine—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000222	0.000837	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000221	0.000832	CcSEcCtD
Dexmedetomidine—Rash—Indinavir—acquired immunodeficiency syndrome	0.00022	0.00083	CcSEcCtD
Dexmedetomidine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00022	0.000829	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000219	0.000826	CcSEcCtD
Dexmedetomidine—Headache—Indinavir—acquired immunodeficiency syndrome	0.000219	0.000824	CcSEcCtD
Dexmedetomidine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000218	0.000822	CcSEcCtD
Dexmedetomidine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000216	0.000814	CcSEcCtD
Dexmedetomidine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000212	0.000798	CcSEcCtD
Dexmedetomidine—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000212	0.000798	CcSEcCtD
Dexmedetomidine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.00021	0.000791	CcSEcCtD
Dexmedetomidine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000209	0.000787	CcSEcCtD
Dexmedetomidine—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000208	0.000784	CcSEcCtD
Dexmedetomidine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000208	0.000783	CcSEcCtD
Dexmedetomidine—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000207	0.000782	CcSEcCtD
Dexmedetomidine—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000207	0.000779	CcSEcCtD
Dexmedetomidine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000201	0.000756	CcSEcCtD
Dexmedetomidine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.0002	0.000753	CcSEcCtD
Dexmedetomidine—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000199	0.00075	CcSEcCtD
Dexmedetomidine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000199	0.000749	CcSEcCtD
Dexmedetomidine—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000198	0.000745	CcSEcCtD
Dexmedetomidine—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000196	0.000739	CcSEcCtD
Dexmedetomidine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000193	0.000727	CcSEcCtD
Dexmedetomidine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000192	0.000724	CcSEcCtD
Dexmedetomidine—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000187	0.000707	CcSEcCtD
Dexmedetomidine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000186	0.0007	CcSEcCtD
Dexmedetomidine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000185	0.000699	CcSEcCtD
Dexmedetomidine—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000184	0.000694	CcSEcCtD
Dexmedetomidine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000184	0.000693	CcSEcCtD
Dexmedetomidine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000183	0.000691	CcSEcCtD
Dexmedetomidine—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000183	0.000689	CcSEcCtD
Dexmedetomidine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000178	0.000673	CcSEcCtD
Dexmedetomidine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000177	0.000668	CcSEcCtD
Dexmedetomidine—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000177	0.000668	CcSEcCtD
Dexmedetomidine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000177	0.000667	CcSEcCtD
Dexmedetomidine—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000176	0.000663	CcSEcCtD
Dexmedetomidine—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000173	0.000653	CcSEcCtD
Dexmedetomidine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.00017	0.000642	CcSEcCtD
Dexmedetomidine—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000169	0.000637	CcSEcCtD
Dexmedetomidine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000169	0.000636	CcSEcCtD
Dexmedetomidine—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000168	0.000633	CcSEcCtD
Dexmedetomidine—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000167	0.000629	CcSEcCtD
Dexmedetomidine—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000159	0.0006	CcSEcCtD
Dexmedetomidine—ADRA2B—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	3.93e-06	0.00383	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.84e-06	0.00374	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.84e-06	0.00374	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	3.84e-06	0.00374	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.81e-06	0.00371	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.76e-06	0.00366	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.75e-06	0.00365	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.69e-06	0.0036	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.68e-06	0.00358	CbGpPWpGaD
Dexmedetomidine—ADRA2C—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	3.67e-06	0.00357	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.66e-06	0.00357	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	3.65e-06	0.00355	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	3.51e-06	0.00341	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.47e-06	0.00338	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.47e-06	0.00338	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	3.47e-06	0.00338	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	3.46e-06	0.00337	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.46e-06	0.00337	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.46e-06	0.00337	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.45e-06	0.00336	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	3.42e-06	0.00333	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	3.41e-06	0.00332	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	3.4e-06	0.00331	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.39e-06	0.00331	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.39e-06	0.0033	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	3.35e-06	0.00326	CbGpPWpGaD
Dexmedetomidine—ADRA2A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	3.31e-06	0.00322	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.31e-06	0.00322	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—TAT—acquired immunodeficiency syndrome	3.29e-06	0.00321	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.24e-06	0.00316	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.24e-06	0.00316	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	3.24e-06	0.00315	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.19e-06	0.00311	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.19e-06	0.00311	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	3.19e-06	0.0031	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.17e-06	0.00308	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	3.12e-06	0.00304	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.12e-06	0.00304	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.1e-06	0.00302	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.09e-06	0.00301	CbGpPWpGaD
Dexmedetomidine—SLC6A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.08e-06	0.003	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	3.07e-06	0.00299	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.04e-06	0.00296	CbGpPWpGaD
Dexmedetomidine—ADRA2A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	2.98e-06	0.0029	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—IFNA1—acquired immunodeficiency syndrome	2.97e-06	0.00289	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	2.94e-06	0.00286	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.92e-06	0.00285	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.92e-06	0.00284	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.87e-06	0.0028	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.86e-06	0.00279	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.82e-06	0.00275	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.82e-06	0.00274	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.8e-06	0.00273	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—AGPS—acquired immunodeficiency syndrome	2.8e-06	0.00273	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—IFNA1—acquired immunodeficiency syndrome	2.78e-06	0.0027	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.77e-06	0.00269	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	2.75e-06	0.00267	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—TAT—acquired immunodeficiency syndrome	2.67e-06	0.0026	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.64e-06	0.00257	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.63e-06	0.00257	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.63e-06	0.00256	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.63e-06	0.00256	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.63e-06	0.00256	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.57e-06	0.00251	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	2.55e-06	0.00249	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	2.55e-06	0.00249	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.51e-06	0.00244	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.47e-06	0.0024	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—TAT—acquired immunodeficiency syndrome	2.46e-06	0.00239	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.43e-06	0.00236	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	2.38e-06	0.00232	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.38e-06	0.00232	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.37e-06	0.00231	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.33e-06	0.00227	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—CSF2—acquired immunodeficiency syndrome	2.33e-06	0.00227	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.32e-06	0.00226	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—TAT—acquired immunodeficiency syndrome	2.31e-06	0.00225	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.31e-06	0.00225	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AGPS—acquired immunodeficiency syndrome	2.27e-06	0.00221	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—IFNA1—acquired immunodeficiency syndrome	2.26e-06	0.0022	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	2.23e-06	0.00217	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	2.23e-06	0.00217	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.22e-06	0.00216	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.22e-06	0.00216	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.22e-06	0.00216	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.19e-06	0.00213	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.17e-06	0.00212	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.17e-06	0.00212	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—CSF2—acquired immunodeficiency syndrome	2.17e-06	0.00212	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.1e-06	0.00204	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.09e-06	0.00204	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.09e-06	0.00203	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.09e-06	0.00203	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.01e-06	0.00195	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2e-06	0.00195	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2e-06	0.00195	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2e-06	0.00195	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.97e-06	0.00192	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.97e-06	0.00192	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.97e-06	0.00192	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.96e-06	0.00191	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.96e-06	0.00191	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.96e-06	0.00191	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.95e-06	0.0019	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.93e-06	0.00188	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.92e-06	0.00187	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.89e-06	0.00184	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.87e-06	0.00182	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.87e-06	0.00182	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.84e-06	0.00179	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.84e-06	0.00179	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.83e-06	0.00178	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.83e-06	0.00178	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.81e-06	0.00176	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.81e-06	0.00176	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.8e-06	0.00176	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.8e-06	0.00176	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.8e-06	0.00176	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.78e-06	0.00173	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.78e-06	0.00173	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.77e-06	0.00172	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.76e-06	0.00172	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	1.74e-06	0.0017	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.74e-06	0.0017	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.69e-06	0.00165	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.67e-06	0.00162	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.66e-06	0.00162	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.66e-06	0.00162	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.65e-06	0.00161	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.64e-06	0.00159	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.64e-06	0.00159	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.63e-06	0.00159	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.59e-06	0.00155	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.59e-06	0.00155	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.58e-06	0.00154	CbGpPWpGaD
Dexmedetomidine—SLC6A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.56e-06	0.00152	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.52e-06	0.00148	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.52e-06	0.00148	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—ALB—acquired immunodeficiency syndrome	1.52e-06	0.00148	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.5e-06	0.00146	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.49e-06	0.00145	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.49e-06	0.00145	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.49e-06	0.00145	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.49e-06	0.00145	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.48e-06	0.00144	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.48e-06	0.00144	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	1.48e-06	0.00144	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.47e-06	0.00143	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.44e-06	0.0014	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—ALB—acquired immunodeficiency syndrome	1.42e-06	0.00138	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.39e-06	0.00136	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.37e-06	0.00134	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.37e-06	0.00134	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.37e-06	0.00134	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.37e-06	0.00133	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.36e-06	0.00132	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.35e-06	0.00132	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.35e-06	0.00132	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.35e-06	0.00132	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.35e-06	0.00132	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.34e-06	0.00131	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.33e-06	0.0013	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.32e-06	0.00128	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.27e-06	0.00123	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.26e-06	0.00122	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.26e-06	0.00122	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.25e-06	0.00121	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.25e-06	0.00121	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.24e-06	0.00121	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.24e-06	0.00121	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.24e-06	0.0012	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—IL2—acquired immunodeficiency syndrome	1.23e-06	0.0012	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.23e-06	0.0012	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.22e-06	0.00119	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.17e-06	0.00114	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.17e-06	0.00114	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.16e-06	0.00113	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	1.15e-06	0.00112	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—IL2—acquired immunodeficiency syndrome	1.15e-06	0.00112	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.14e-06	0.00111	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.14e-06	0.00111	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.13e-06	0.0011	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.12e-06	0.00109	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.12e-06	0.00109	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.12e-06	0.00109	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.05e-06	0.00102	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.05e-06	0.00102	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.05e-06	0.00102	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.03e-06	0.001	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.03e-06	0.001	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.02e-06	0.000993	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.01e-06	0.000986	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.83e-07	0.000957	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.83e-07	0.000957	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.67e-07	0.000942	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.67e-07	0.000942	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.39e-07	0.000914	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	9.33e-07	0.000908	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	9.26e-07	0.000902	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	9.06e-07	0.000883	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.87e-07	0.000863	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.73e-07	0.000851	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.6e-07	0.000838	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.49e-07	0.000827	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.01e-07	0.00078	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.99e-07	0.000778	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.98e-07	0.000777	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.98e-07	0.000777	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.89e-07	0.000768	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.81e-07	0.000761	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.77e-07	0.000756	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.48e-07	0.000728	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.37e-07	0.000717	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.36e-07	0.000717	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.26e-07	0.000707	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.25e-07	0.000706	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.21e-07	0.000702	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.14e-07	0.000695	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.05e-07	0.000687	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.74e-07	0.000656	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.63e-07	0.000646	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.59e-07	0.000642	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.48e-07	0.000632	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.07e-07	0.000591	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.98e-07	0.000583	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.89e-07	0.000574	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.78e-07	0.000563	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	5.74e-07	0.000559	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.47e-07	0.000533	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.35e-07	0.000521	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	4.66e-07	0.000454	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.62e-07	0.000449	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.59e-07	0.000447	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ALB—acquired immunodeficiency syndrome	4.28e-07	0.000417	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.17e-07	0.000406	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.15e-07	0.000404	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ALB—acquired immunodeficiency syndrome	4.04e-07	0.000393	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.89e-07	0.000379	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.87e-07	0.000377	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.83e-07	0.000373	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.81e-07	0.000371	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.16e-07	0.000308	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.15e-07	0.000306	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	3.04e-07	0.000296	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.71e-07	0.000264	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	2.57e-07	0.000251	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.45e-07	0.000239	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.29e-07	0.000223	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.25e-07	0.000219	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.86e-07	0.000181	CbGpPWpGaD
